Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after taxus liberte Paclitaxel-eluting coronary stent placement

Authors

K. N. Garratt, Hofstra Northwell School of Medicine
W. D. Weaver
R. G. Jenkins
T. K. Pow
L. Mauri
D. J. Kereiakes
K. J. Winters
T. Christen
D. J. Allocco
D. P. Lee

Publication Date

2015

Journal Title

Circulation

Abstract

BACKGROUND: The TAXUS Liberte Post Approval Study (TL-PAS) contributed patients treated with TAXUS Liberte paclitaxel-eluting stent and prasugrel to the Dual Antiplatelet Therapy Study (DAPT) that compared 12 and 30 months thienopyridine plus aspirin therapy after drug-eluting stents. METHODS AND RESULTS: Outcomes for 2191 TL-PAS patients enrolled into DAPT were assessed. The DAPT coprimary composite end point (death, myocardial infarction [MI], or stroke) was lower with 30 compared with 12 months prasugrel treatment (3.7% versus 8.8%; hazard ratio [HR], 0.407; P30 months. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00997503.

Volume Number

131

Issue Number

1

Pages

62-73

Document Type

Article

EPub Date

2014/11/18

Status

Faculty

Facility

School of Medicine

Primary Department

Cardiology

PMID

25400062

DOI

10.1161/circulationaha.114.013570